Le Lézard
Classified in: Health, Science and technology
Subject: FDA

Shoulder Innovations Announces FDA 510(k) Clearance For Shoulder Technology


HOLLAND, Mich., Nov. 5, 2018 /PRNewswire/ -- Shoulder Innovations announced today that they have received FDA clearance for their InSet Humeral Short Stem System.  This is a key addition to their expanding shoulder portfolio and another milestone for their vision to offer a complete leading technology shoulder arthroplasty product line.

Shoulder Innovations company logo

The clearance covers products used for partial or total shoulder arthroplasty used in the treatment of degenerative, rheumatoid or traumatic arthritis in the shoulder.  The new InSet Shoulder system provides innovative features and solutions to address potential problems encountered with current total shoulder replacement systems. 

Peter Johnston, M.D. of Southern Maryland Orthopaedic and Sports Medicine said, "The strengths of the InSet Shoulder System are its streamlined instrumentation, proprietary coating technology for implant fixation with bone preservation and ability to reproduce native humeral anatomy.  The system is game-changing." 

Robert Tashjian, M.D. of the University of Utah added, "The combination of the InSet Humeral Stem and Shoulder Innovation's unique InSet glenoid implant affords a surgically simple, bone sparing option for many types of humeral or glenoid deformities associated with arthritis."

Rob Ball, Executive Chairman of Shoulder Innovations said, "We are excited to see the fast-paced progress and results made by the team. Genesis Innovation Group has moved rapidly in developing this highly innovative new product line.  It plays a pivotal role in the Shoulder Innovations strategy, and Genesis has proven to be an excellent partner in helping our company move forward."

Shoulder Innovations has also recently announced new investments that will be used to fuel new product development, and to acquire inventory and assets to accelerate growth of its current InSet platform technology.  This technology serves as a foundational platform on which many future products and systems are in development. 

The long-term vision of Shoulder Innovations is to offer a complete leading technology shoulder arthroplasty product line.

About Shoulder Innovations:
Shoulder Innovations, LLC is a medical device development company which designs and commercializes innovative products which demonstrate the potential for improved patient care and reduced overall cost to the healthcare system.  

Leveraging its breakthrough, patented, inset glenoid design, Shoulder Innovations is commercializing a shoulder replacement implant system focused on improving outcomes related to the greatest cause of shoulder replacement failure: glenoid loosening.  

The InSet technology has been shown in testing to significantly reduce glenoid implant micro-motion and simplifies the surgical technique, potentially reducing complications or increase implant longevity.

Shoulder Innovations is based in Holland, Mich.  

Learn more about Shoulder Innovations and its Total Shoulder Replacement System at shoulderinnovations.com.

 

SOURCE Shoulder Innovations


These press releases may also interest you

at 07:15
IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") , InterSystems, a creative data technology provider dedicated to helping customers solve their most critical scalability, interoperability, and speed challenges, together with ImmunoPrecise...

at 07:10
Can-Fite BioPharma Ltd. , a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced financial results and clinical updates for the twelve months ended...

at 07:10
Kelonia Therapeutics, a biotech company revolutionizing in vivo gene delivery, today announced the appointments of global leaders in cell therapy and drug development, Kristen Hege, M.D., and Mathai Mammen, M.D., Ph.D., to its board of directors....

at 07:05
Aldeyra Therapeutics, Inc. (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the clinical development plan intended to enable...

at 07:05
Mythic Therapeutics, a clinical-stage biotechnology company committed to the development of next-generation antibody-drug conjugate (ADC) therapies for the treatment of a wide range of cancers, announced that George Eliades, Ph.D., has joined the...

at 07:05
Seres Therapeutics, Inc. ("Seres" or the "Company"), a leading microbiome therapeutics company, today announced that on March 25, 2024, the Compensation and Talent Committee of Seres' board of directors granted inducement equity grants covering an...



News published on and distributed by: